München
06.06.25 | 08:17
0,891 Euro
-0,11 % -0,001
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| DIAMYD MEDICAL Aktie jetzt für 0€ handeln | |||||
| 19.05. | Diamyd Medical AB (publ): Diamyd Medical appoints Niklas Axelsson as CFO | 69 | GlobeNewswire (Europe) | Niklas Axelsson has been appointed CFO of Diamyd Medical. He will assume his position in August and will also join the management team. Niklas Axelsson brings more than 25 years of experience across... ► Artikel lesen | |
| 15.05. | DIAMYD MEDICAL AB: Adjustment of the number of shares and share capital in Diamyd Medical, receives SEK 1.6 million more than previously communicated | 3 | Cision News | ||
| 05.05. | DIAMYD MEDICAL AB: Diamyd Medical has expanded the recently completed rights issue with a directed new issue of SEK 41.6 million | 8 | Cision News | ||
| 30.04. | DIAMYD MEDICAL AB: Diamyd Medical announces final outcome in oversubscribed rights issue: SEK 224 million | 3 | Cision News | ||
| 30.04. | DIAMYD MEDICAL AB: Diamyd Medical updates the preliminary outcome and will exercise the additional unit issue following the oversubscribed rights issue, raising approximately SEK 224 million | 2 | Cision News | ||
| 29.04. | DIAMYD MEDICAL AB: Diamyd Medical's rights issue has been preliminarily subscribed to 95 percent, thereby raising approximately SEK 198 million | 1 | Cision News | ||
| 28.04. | DIAMYD MEDICAL AB: Last day of the subscription period in Diamyd Medicals rights issue | 1 | Cision News | ||
| 28.04. | DIAMYD MEDICAL AB: Europe to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in autoimmune diabetes | 1 | Cision News | ||
| 25.04. | Diamyd Medical AB (publ): Diamyd Medical's pivotal Phase 3 Type 1 Diabetes trial clears second-to-last safety review ahead of early readout in March 2026 | 81 | GlobeNewswire (Europe) | The independent Data Safety Monitoring Board (DSMB) has completed its fifth scheduled safety review of Diamyd Medical's registrational Phase 3 trial, DIAGNODE-3, evaluating the precision medicine immunotherapy... ► Artikel lesen | |
| 22.04. | DIAMYD MEDICAL AB: Shareholders in Diamyd Medical, including the Chairman of the Board, have provided additional subscription commitments in the ongoing rights issue | 2 | Cision News | ||
| 21.04. | Diamyd Medical AB: Diamyd Medical highlights opportunity in Type 1 Diabetes prevention, adult-onset market, and upcoming Phase 3 readout | 288 | PR Newswire | STOCKHOLM, April 21, 2025 /PRNewswire/ -- In a recent investor interview, Diamyd Medical Board Member Professor Mark Atkinson and CEO Ulf Hannelius shared key insights into the Company's... ► Artikel lesen | |
| 17.04. | DIAMYD MEDICAL AB: The prevention trial DiaPrecise with Diamyd® clears first safety milestone | 1 | Cision News | ||
| 15.04. | Diamyd Medical AB (publ): Australia grants Diamyd Medical patent for novel antigen combination in autoimmune diabetes treatment | 132 | GlobeNewswire (Europe) | The Australian Patent Office has granted a patent protecting a novel immunotherapeutic composition developed by Diamyd Medical for use in the treatment and prevention of autoimmune diabetes. The patent... ► Artikel lesen | |
| 14.04. | DIAMYD MEDICAL AB: Diamyd Medical publishes prospectus with regards to the rights issue | 1 | Cision News | ||
| 09.04. | Diamyd Medical AB (publ): Quarterly Report 2 24/25 | 118 | GlobeNewswire (Europe) | Diamyd Medical today announces in its second quarterly report for fiscal year 2024/2025 continued progress toward a transformative regulatory milestone, with early Phase 3 results from the DIAGNODE-3... ► Artikel lesen | |
| 09.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.04.2025 | 140 | Xetra Newsboard | Das Instrument N7S CA87043J2039 SWEET POISON SPIRITS INC. EQUITY wird cum Kapitalmassnahme gehandelt am 09.04.2025 und ex Kapitalmassnahme am 10.04.2025 The instrument N7S CA87043J2039 SWEET POISON... ► Artikel lesen | |
| 21.03. | DIAMYD MEDICAL AB: Diamyd Medical announces additional subscription commitments for upcoming rights issue | 1 | Cision News | ||
| 17.03. | DIAMYD MEDICAL AB: Diamyd Medical highlights clinical benefits of C-peptide preservation at ATTD 2025 | 1 | Cision News | ||
| 13.03. | Diamyd Medical AB (publ): Diamyd Medical advances AI-powered screening for Type 1 Diabetes within the ASSET Project | 136 | GlobeNewswire (Europe) | Diamyd Medical, in collaboration with Mainly AI and ASSET partners, highlights meaningful progress in AI-driven screening and risk prediction for Type 1 Diabetes at the Advanced Technologies & Treatments... ► Artikel lesen | |
| 10.03. | DIAMYD MEDICAL AB: Diamyd Medical announces additional subscription commitments for upcoming rights issue | 3 | Cision News |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 166,40 | -0,12 % | AbbVie continues gains for seven straight sessions | ||
| INNOCAN PHARMA | 0,111 | +2,31 % | Unglaubliche Prognose für Montag setzt Innocan Pharma Aktionäre unter Druck. Jetzt Sondermeldung lesen und Montag reagieren! | ||
| ABBOTT LABORATORIES | 117,80 | +1,38 % | Pressmaster DMCC: Veteran-Owned Nate Woodard Acquires Abbotts Uniforms, Continuing Legacy of Excellence in Military and Uniformed Servicewear | Quantico, Virginia--(Newsfile Corp. - June 4, 2025) - Nate Woodard, a veteran-owned small business known for its commitment to craftsmanship and service, is proud to announce the acquisition of Abbott... ► Artikel lesen | |
| ARZNEIWERK AG VIDA | 0,695 | +10,32 % | PTA-AFR: Arzneiwerk AG VIDA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Arzneiwerk AG VIDA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Arzneiwerk... ► Artikel lesen | |
| ZOETIS | 149,44 | +0,15 % | Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio? | ||
| CRESCO LABS | 0,496 | +1,85 % | Canaccord Genuity stuft Cresco Labs-Aktie aufgrund von Wettbewerbsdruck herab | ||
| CSPC PHARMA | 0,988 | +1,58 % | Dividendenbekanntmachungen (04.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADESSO SE DE000A0Z23Q5 - 0,75 EUR AGEAS SA/NV BE0974264930 - 2 EUR AIR LEASE CORPORATION US00912X3026 0,22 USD 0,1934 EUR ANALOG... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 36,000 | +1,12 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction | Investigator-initiated Phase 2 trial to evaluate TNX-102 SL's potential to reduce severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD) Trial is sponsored by the University... ► Artikel lesen | |
| AMARIN | 10,600 | -5,36 % | XFRA EH3: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 0,602 | +3,35 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS0977021049 Bolt Biotherapeutics Inc. 06.06.2025 US0977022039 Bolt Biotherapeutics Inc. 09.06.2025 Tausch 20:1SE0018041097 Spotr... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 97,96 | -0,22 % | Axsome Therapeutics bei Jefferies: Strategisches Wachstum und Pipeline-Erweiterung | ||
| WUXI BIOLOGICS | 2,701 | -2,17 % | WuXi Biologics-Aktie leicht im Plus (2,7895 €) | Am Aktienmarkt notiert das Wertpapier von WuXi Biologics derzeit fester. Das Papier notiert gegenwärtig bei 2,79 Euro. An der Börse hat sich heute der Anteilsschein von WuXi Biologics zwischenzeitlich... ► Artikel lesen | |
| JAGUAR HEALTH | 3,885 | -2,88 % | Jaguar Health, Inc.: Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series | Click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 6, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate... ► Artikel lesen | |
| DAIICHI SANKYO | 21,120 | -0,66 % | AstraZeneca And Daiichi Sankyo's ENHERTU Shows Significant Survival Benefit In Phase 3 Gastric Cancer Trial | LONDON (dpa-AFX) - AstraZeneca (AZN, AZN.L) and Daiichi Sankyo (DSKYF.PK) announced that positive results from the DESTINY-Gastric04 phase 3 trial showed ENHERTU (trastuzumab deruxtecan) demonstrated... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 19,085 | -1,01 % | JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory |
Das Unternehmen DIAMYD MEDICAL AB kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,001 (-0,11 %) liegt der Kurs bei 0,891 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAMYD MEDICAL AB finden Sie auf Wallstreet Online.